Biomarin Pharmaceutical (BMRN) Total Liabilities (2009 - 2026)

Biomarin Pharmaceutical has disclosed Total Liabilities across 18 years of filings, most recently posting $2.4 billion for Q1 2026.

• Quarterly Total Liabilities rose 75.75% year-over-year to $2.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 75.75% YoY) and the FY2025 annual result came in at $1.5 billion, up 13.23% from the prior year.
• Total Liabilities rose to $2.4 billion in Q1 2026, from $1.5 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $2.4 billion in Q1 2026 and troughed at $1.3 billion in Q4 2024.
• A 5-year average of $1.7 billion and a median of $1.7 billion in 2022 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities fell 29.58% — and 2026, when it soared 75.75%.
• Tracing BMRN's Total Liabilities over 5 years: stood at $1.8 billion in 2022, then rose by 6.67% to $1.9 billion in 2023, then slipped by 29.58% to $1.3 billion in 2024, then gained by 13.23% to $1.5 billion in 2025, then surged by 57.85% to $2.4 billion in 2026.
• Business Quant data shows BMRN's Total Liabilities at $2.4 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.6 billion in Q3 2025.